AI Offers New Pathways to Strengthen Site Leadership
Artificial intelligence can help identify key opinion leaders in emerging markets, improving site influence, patient engagement, and trial success.
Gen Li, PhD, MBA, president of Phesi, discussed results from the company's analysis on global inequity in breast cancer development in a recent video interview with Applied Clinical Trials.
- Geographic concentration of breast cancer trial leaders is in the US and China.
- Operational barriers in lower-income countries are due to traditional business models.
- AI and machine learning can implement a more patient-centric approach.
Li emphasized the importance of identifying local leaders and redistributing trial workloads to improve recruitment.
Author's summary: AI improves site leadership in underserved regions.